Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus
conventional loading dose(180mg) will result in a higher inhibition of platelet
aggregation(IPA) without increasing the bleeding events.